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This article is the result of a round table discussion 
held at the European Lung Cancer Conference (ELCC) 
in Geneva in May 2017. Its purpose is to explore and 
discuss the advances in the knowledge about the biology 
and treatment of brain metastases originating from non-
small cell lung cancer. The authors propose a series of 
recommendations for research and treatment within the 
discussed context.
IntroduCtIon
Recent insights into the biology of non-small 
cell lung cancer (NSCLC) have led to a 
wealth of novel therapies, including targeted 
agents and immune checkpoint inhibitors 
with significant clinical activity. So far, there 
are limited data on the efficacy of these 
drugs in patients with brain metastases (BMs) 
but intracranial responses have been docu-
mented in emerging studies.
At the meeting, a multidisciplinary group 
of experts discussed the biology of BMs 
as well as the anatomy of the blood–brain 
barrier (BBB). The group considered treat-
ment options for NSCLC and their effect 
on BMs, focusing on targeted treatment and 
combination treatment for epidermal growth 
factor receptor (EGFR) mutated NSCLC 
and those with anaplastic lymphoma kinase 
(ALK) rearrangement.
Incidence of BMs in nSCLC
BMs are the most common intracranial 
neoplasms with significant morbidity and 
mortality.1 2 In lung cancer, 30–50% of 
patients will be diagnosed with BMs during 
their disease, with rising frequency because 
of the availability of novel imaging tech-
niques and improved survival rates. Fifty per 
cent of lung cancer BMs occur at disease 
presentation and 50–60% as the only site of 
distant disease. BMs often present as multiple 
lesions, although in one third of patients BMs 
are singular.
BMs occur initially in 20% of patients 
with NSCLC,1 in 10–20% with advanced 
NSCLC,3 with numbers as high as 40–50% 
in those with stage III lung adenocarci-
noma,4 20–40% in those with ALK-rear-
ranged tumours,5 and 45–70% in those who 
have ALK-rearranged NSCLCs and have 
been pretreated with an appropriate tyrosine 
kinase inhibitor (TKI).3
EGFR-activating mutations are present 
in about 10–20% of white patients with 
NSCLC.6 7 In patients with EGFR mutation, 
the incidence of BMs at the time of diag-
nosis is 25%, which is slightly higher than in 
unselected patients, suggesting that EGFR 
mutations might be associated with a meta-
static tropism to the brain and then with an 
increased risk of BMs.8 9 Furthermore, the 
brain is a common site for relapse of disease 
in patients previously treated with TKIs in 
about 30–60% of EGFR-mutated NSCLCs.10
Prognosis of BMs
Overall survival (OS) of patients after the diag-
nosis of BMs remains poor with significant 
clinical problems. The prognosis depends on 
the patient’s age and performance status, the 
type of the primary tumour, the time from 
diagnosis of the primary, the overall disease 
activity, and the location and extension of 
extracranial and intracranial disease.11–14
Biology and molecular alterations of nSCLC BMs
There are many biological aspects of growth 
of metastases in the brain for which scien-
tific progress has been made and where 
further progress in our understanding will be 
helpful in developing new treatments. This 
extends from the biology of brain colonisa-
tion by metastatic cells from the initial stages 
(asymptomatic metastases) to advanced 
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The use of experimental models has allowed construc-
tion of a sequential map showing key mechanisms of a 
metastatic cell developing in the brain (see figure 1).
Crossing the BBB
The ability of cancer cells to cross the BBB involves general 
and specific mediators.15–18
The naive brain microenvironment
After extravasation most metastatic cells die, partly due 
to reactions of the brain microenvironment responding 
to their presence.19–21 This suggests that a naive brain 
microenvironment initially repels many potential cancer 
cells. Some molecular mediators of natural defences 
have been reported.20 21 It is also true, unfortunately, 
that some metastatic cancer cells avoid this initial bottle-
neck by blocking anti-tumour components of the reactive 
microenvironment.20 21 The surviving cells closely interact 
with pre-existing blood vessels in the brain by vascular 
co-option and colonisation of the crucial perivascular 
niche.19 21 22 This is all mandatory to the final progression 
to brain macrometastases.
Vascular co-option and dormancy
This process is mediated by cancer cell adhesion mole-
cules and integrins,21 23 as well as by secreted molecules 
from the co-opted endothelial cells.24 25 Brain metas-
tasis can manifest many years after the diagnosis of the 
primary tumour. Dormancy/quiescence is thought to 
play an important role in brain metastasis and recent data 
have started to show mediators of this biology,26 which is 
also linked to the perivascular location. Eventually these 
cells will re-awake and start to grow aggressively. The 
mechanism mediating this process has been linked to 
the ability of cancer cells to recognise components of the 
basal lamina.23 27
Angiogenesis
Additional ways to interact with the vasculature involve 
the formation of new blood vessels, called angiogenesis. 
This appears crucial for the formation of BMs from lung 
adenocarcinoma, in an entity-specific and organ-specific 
manner. Interestingly, inhibition of this early angiogenic 
switch prevented metastases from outgrowth and arrested 
them in a microscopic state, making angiogenesis inhibi-
tion an interesting approach for BM prevention in lung 
adenocarcinoma.19 28
Invasive fronts
Even though the mechanisms of brain colonisation are 
more linked to the initial stages of metastasis, some might 
also apply to advanced stages of the disease and thus offer 
opportunities for improved therapies. For instance, inva-
sive fronts have been described in 50% of BMs, which in 
many cases correlates with the process of vascular co-op-
tion.29 The correlation of invasive fronts with poor prog-
nosis in patients with BMs30 might offer a therapeutic 
window to target mediators of vascular co-option after 
surgery to reduce local relapse.
Genomic alterations
Therapies, including targeted ones that are effective 
outside the brain, can fail in this organ; reasons for 
this might include the genomic and other molecular 
divergence of BMs compared with primary tumours 
and other metastatic sites.31–37 Although still in need of 
Figure 1 Key mechanisms of a metastatic cell developing in the brain (see reference22).
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more evidence for their contribution to BM progression, 
specific genomic alterations found in brain metastasis 
offer actionable mutations to be exploited. In addition, 
BM-specific mutations could also be found in liquid 
biopsies from blood or cerebrospinal fluid (CSF) and 
have been used to evaluate response to therapy and the 
presence of residual disease.33 36 This emerging field of 
BM would benefit from the use of recent advances in 
genetic engineering using CRISPR/Cas9 combined with 
experimental models.
Cancer cell–brain microenvironment interaction as target for 
therapy and prevention
The divergent evolution of metastatic cells in the brain 
might respond to the significant pressure generated 
by its environment that is made of different cellular 
components, and homeostatic regulation. The microen-
vironment thus might be a crucial pillar to explain the 
specificity that applies to brain metastasis. Close cancer 
cell–microenvironment interactions have created an 
interesting scenario, where experimental therapies have 
probed the critical support that cancer cells receive 
from altered components of the microenvironment. For 
instance, established BMs have been shown to assemble 
gap junctions with surrounding reactive astrocytes.38–42 
This interaction can allow metastatic cells to detoxify 
themselves from the accumulation of potentially toxic 
metabolites generated by various sources of stress, 
including chemotherapy.42 A combination of BBB-perme-
able drugs targeting gap junctions has recently supported 
the potential of targeting interactions with the microen-
vironment. This might offer BM-specific therapies and 
prevention strategies in the future, possibly independent 
of the tumour entity.
the reLevanCe of the BBB for MedICaL treatMent of 
nSCLC BMS
The BBB is the physical, chemical and metabolic barrier 
that segregates blood from the interstitial fluid of the 
central nervous system (CNS) for protection of the CNS 
against overexposure, pathogens and toxins. Molecules 
with a molecular weight over 500 Daltons (the molecular 
weight of 98% of drugs) are generally considered to not 
readily cross an intact BBB, but other physico-chemical 
properties also influence brain penetration. This is impor-
tant for primary and secondary prophylaxis; however, 
mixed responses have been seen.
The rising incidence of BMs may be partly due to 
the fact that some therapeutic compounds can control 
tumour growth outside of the CNS but do not, or only 
partially, penetrate the BBB.43 Therefore, tumour cells 
that have successfully invaded the brain may not be 
affected by these agents, making the brain a potential 
‘sanctuary site’ for cancers.44
There is an ongoing controversy about the role of the 
BBB breakdown in affecting the activity of systemic ther-
apies for BMs.45 46 In health, but also many CNS diseases, 
the specific anatomical and molecular constitution of the 
BBB limits access of the vast majority of molecules to the 
brain: specialised endothelial cells connected by tight 
junctions, the vascular basement membrane, pericytes, 
astrocytic foot processes, and specialised transporter 
systems strictly regulate extravasation, while active exclu-
sion mechanisms like glycoprotein P (P-gp), breast cancer 
resistance protein (BCRP) and the family of multidrug-re-
sistant proteins exclude xenobiotics effectively.47 Thus, 
the BBB remains a complex obstacle for drug delivery to 
the CNS. Several techniques have been tested to direct 
therapeutics across the BBB, including disruption of the 
BBB, modification of drugs, inhibition of efflux transport, 
and Trojan horse approaches that use endogenous trans-
porter properties of the BBB.48 One problem with those 
approaches is that even if an active compound can cross 
the endothelium, it is not guaranteed that it will reach 
the target cell. Recent evidence suggests that lowering 
the affinity of an antibody directed against the transferrin 
receptor allows for greater release of the antibody on the 
abluminal surface of the vessel, and entry into the brain 
parenchyma.47 49
The majority of brain macrometastases, that is, metas-
tases of more than 1 mm diameter which are detectable 
with common imaging techniques, do show signs of 
disturbance of the BBB, although to a varying extent.50–53 
Therefore, the challenges of crossing the normal BBB 
do not fully apply to BMs, even though some aspects of 
the BBB are preserved in BMs. It is a matter of debate 
whether a BBB breakdown in brain tumours allows pene-
tration of systemic chemotherapies to the single cancer 
cells of the brain tumour in sufficient concentrations. 
In clinical specimens, highly variable tumour levels have 
been reported for different agents.54 55 Of note, lapatinib 
and trastuzumab, two agents with no significant activity 
against breast cancer BMs, can be found in relevant 
concentrations in BMs in clinical and preclinical speci-
mens, which makes it highly likely that the BBB is only 
partially relevant for the lack of CNS activity of some 
drugs.55 56 In accordance with this, it has been demon-
strated that trastuzumab-emtansin (T-DM1), a derivate of 
trastuzumab, is able to show signs of clinical effectivity in 
HER2-overexpressing BMs, further supporting the notion 
that it is not the BBB penetration but other microenvi-
ronmental mechanisms in the brain that make certain 
drugs ineffective.57
It has been shown that increased BBB permeability 
is associated with accelerated metastasis growth.58 Two 
closely related mTOR/PI3K inhibitors, one of them 
with a minor chemical modification that allows the two 
main exclusion transporters constituting the BBB (P-gp 
and BCRP)59 to be bypassed, had different effects on 
these metastases: while the BBB non-permeable inhibitor 
only affected permeable metastases, the BBB permeable 
one had strong anti-tumour effects on non-permeable 
micrometastases, and even dormant cancer cells in the 
brain.58 Furthermore, nuclear morphology changes and 
single cell regression patterns implied that both 
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inhibitors target cancer cells independently of their rela-
tive position to the blood vessel, making BBB permea-
bility the limiting step for drug diffusion to cancer cells 
in the brain.58 Another preclinical study found a highly 
variable uptake of doxorubicin and paclitaxel of different 
metastases from the same breast cancer cell line, so that 
cytotoxic concentrations were reached in only 10% of the 
most permeable metastases.52 It is widely assumed that 
classical chemotherapies with proven activity on systemic 
metastases of many cancers have limited, if any, activity 
on BMs,60 probably with the exception of primary chemo-
therapy of lung cancer BM.61 This can be due to a lack of 
sufficient BBB breakdown to allow primary extravasation 
of the drug and rapid secondary exclusion by P-gp, but 
also specific resistance mechanisms that are different in 
the brain, such as protection of extravasated cancer cells 
by astrocytes38 or other brain resident cells.
treatMent of nSCLC BMS
overview
For a long time, BMs in lung cancer have been considered 
a final event and were treated either by whole brain radi-
ation therapy (WBRT) or palliative care. However, since 
the arrival of new systemic and targeted therapies, more 
effective treatments for BMs are available with the aim to 
increase local control, and if possible survival, without 
affecting neurocognition.
Current treatment algorithms of NSCLC BMs offer 
symptom control measures and therapeutic measures. 
Modern disease-directed management includes:62 
 ► surgical resection,
 ► radiotherapy,
 ► chemotherapy,
 ► targeted drugs,
 ► multi-modality approaches.
Limited metastatic lesions
For limited metastatic lesions (one to three metastases) 
neurosurgical resection is one of the main therapeutic 
options, with stereotactic radiosurgery (SRS) being the 
main alternative, known to be equivalent to surgery in 
term of local control.
Resection can also be combined with radiotherapy, 
such as SRS or WBRT. These combinations have been 
addressed in two recent randomised trials, which showed 
that postoperative SRS was associated with a significant 
increase in local control compared with observation63 and 
that postoperative WBRT was associated with an increase 
in neurocognitive deterioration compared with postoper-
ative SRS without any difference in OS.64
Another approach is the combination of SRS and 
WBRT. One recent randomised trial has shown that even 
if WBRT combined with SRS is associated with better 
brain control, WBRT induces significant higher neuro-
cognitive deterioration compared with SRS alone, without 
any difference in OS.65 However, another randomised 
trial comparing WBRT plus SRS with SRS alone showed 
that for a subgroup of patients with good graded prog-
nostic assessment, a benefit of adding WBRT to SRS was 
obtained in OS.66
While treating patients with WBRT, neurocognition can 
be preserved by performing hippocampal sparing67 or 
adding mementine.68 A randomised phase III clinical trial 
aiming to compare time to neurocognitive failure between 
WBRT plus mementine to WBRT with hippocampal pres-
ervation and mementine is currently being performed ( 
ClinicalTrials. gov identifier: NCT02360215).
Multiple metastatic lesions
In multiple metastatic lesions (more than three BMs) 
WBRT is still an option for most patients, alone or in 
combination with SRS, a radio-sensitiser or chemo-
therapy. However, SRS on more than four and up to 10 
BMs is feasible,69 with no more late toxicity in neurocog-
nition compared with patients with one to four brain 
metastases.70 Some patients, especially those with a poor 
performance status, receive chemotherapy or steroids 
alone.71 The addition of targeted drugs such as erlotinib 
as radio-sensitisers to WBRT has failed to show benefit in 
local controls or OS but has increased toxicity.72–77 The 
addition of chemotherapeutic agents such as temozolo-
mide to radiation has also failed to improve survival but 
increases toxicity.78–82
Systemic chemotherapy
Chemotherapy plays a limited role in the treatment of 
BMs because of its inability to cross the BBB. However, 
response rates as high as 30–40% have been reported in 
the brain with platinum-based chemotherapy, similar to 
rates observed extracranially.61 83
targeted drugs
EGFR TKI therapy
Among patients with NSCLC with EGFR mutations, TKIs 
seem more effective than chemotherapy in controlling 
intracranial disease. EGFR TKIs are low molecular weight 
organic compounds with low to moderate CSF penetra-
tion rates differing between first-generation to third-gen-
eration drugs.84 85
EGFR TKIs of the first generation, such as gefitinib and 
erlotinib, and of the second generation, such as afatinib, 
have recently been integrated in the treatment algo-
rithm of advanced metastatic mutated NSCLC as first-line 
therapy, replacing conventional chemotherapy because 
of improved response and survival rates.86–88
Retrospective data and phase II study experiences have 
indicated that gefitinib and erlotinib have significant 
intracranial activity.89 90
For afatinib, phase II data, results from a compassionate 
use programme as well as pre-specified subgroup analyses 
suggest significant intracranial efficacy. This substanti-
ates preclinical and clinical observations that afatinib can 










pen: first published as 10.1136/esm
oopen-2017-000262 on 26 January 2018. Downloaded from
 
Open Access
5Preusser M, et al. ESMO Open 2018;3:e000262. doi:10.1136/esmoopen-2017-000262 Preusser M, et al. ESMO Open 2018;3:e000262. doi:10.1136/esmoopen-2017-000262
EGFR TKIs of the third generation, such as AZD 3759 
and osimertinib, have recently accelerated the debate 
over the role of modern targeted therapy for the treat-
ment of BMs in mutated NSCLC as a potential substitute 
for brain radiation. This is because of preclinical and clin-
ical evidence proving them to be more effective, showing 
a promising blood brain penetration and the potential 
to overcome EGFR TKI resistance. They also challenge 
the concept of upfront WBRT by being potentially more 
effective but less neurotoxic.94–97
Preclinical studies have shown that osimertinib induces 
sustained tumour regression in an EGFR-mutated PC9 
mouse brain metastasis model,36 and exhibits a greater 
distribution into mouse brain tissue than gefitinib, rocile-
tinib or afatinib. Clinically, osimertinib has greater efficacy 
than platinum/pemetrexed in patients with T790M-pos-
itive NSCLC, including those with CNS metastases in a 
second-line setting.86 95
AZD 3759 has primarily been designed for crossing 
the BBB. Clinical experience for AZD 3759 exists from 
a phase I study in pretreated patients. By dosing up to 
300 mg twice a day, there has been a significantly higher 
tumour shrinkage intracranially than extracranially. 
Grade 4 toxicity of less than 10% was reported for rash, 
diarrhoea and pruritus.96 97
TKIs for patients with ALK-rearranged NSCLC
Currently, there are five compounds registered for 
patients with NSCLC and ALK rearrangement: these are 
the TKIs crizotinib, ceritinib, alectinib, lorlatinib and 
brigatinib. All these compounds have been registered 
with the US Food and Drug Administration (FDA); crizo-
tinib, certinib and alectinib have also been approved by 
the European Medicines Agency (EMA) with an approval 
of brigatinib currently pending.
The development of the ALK-directed TKI crizotinib 
took a rather short time between the discovery of the 
importance of ALK rearrangement and the introduction 
of the drug. In the PROFILE 1014 trial, crizotinib showed 
a significant improvement in progression-free survival 
(PFS) compared with chemotherapy in patients with 
ALK rearrangement.98
The incidence of BMs constitutes a major problem in 
patients with NSCLC and ALK rearrangement. About one 
third of TKI-resistant tumours harbour ALK mutations, 
including an amplification which occurs in 10% of muta-
tions of the remaining 25%.99–103
Therefore, the question arises whether the CNS acts as 
a ‘sanctuary’ for the development of metastases, as up to 
70% of recurrences occur within this anatomic area.
Drugs developed after crizotinib, targeting 
ALK rearrangement, such as ceritinib, alectinib and 
brigatinib, have the ability to induce a remarkable CNS 
response in patients who have been pretreated with 
crizotinib. They have quite a different side-effect profile 
however.
When considering alectinib, responses in the CNS 
were complete in 20% in patients with measurable CNS 
metastases,104 whereas the use of brigatinib in the iden-
tical setting produced intracranial overall response rates 
in 42%–67% of patients.105
Very recent data have shown a significant superiority 
of alectinib over crizotinib in untreated ALK-positive 
NSCLC regarding the duration of PFS and the time until 
CNS progression.106
Nevertheless, the question of the best treatment 
sequence – if any - emerges and will have to be the topic 
of further clinical investigations.
radiotherapy
Apart from surgery and targeted drugs, radiotherapy 
(especially radiosurgery or hypo-fractionated stereotactic 
radiotherapy (HFSRT)) is one of the main weapons to 
increase local control, and if possible survival, without 
affecting neurocognition.
Because the combination of WBRT with SRS or surgery 
does not increase OS but neurocognitive deficit65 107 108 
and because SRS alone compared with the combination 
of SRS with WBRT has been shown to lead to the same 
OS and less neurocognitive deficit, with a shorter time 
to intracranial failure, SRS is now considered a standard 
treatment for patients with BMs.
A study from 2016 showed the relevance of 
postoperative SRS compared with observation, bringing 
better local control without toxicity and no difference 
in OS.109 More recently this has been confirmed by a 
randomised clinical trial showing that postoperative SRS 
led to significantly higher local control than observation, 
with the same OS.63 The trial showed a higher benefit of 
postoperative SRS for small cavities (0–2.5 cm) compared 
with large ones.
Another randomised trial comparing postoperative 
radiation with WBRT plus SRS on non-resected BMs 
versus SRS on the cavity of resected metastases plus SRS 
on non-resected BMs showed that postoperative WBRT 
led to a higher neurocognitive deficit and the same OS 
compared with SRS alone. However, this trial showed 
poorer local control and worse brain control for patients 
treated with postoperative SRS compared with those 
treated with WBRT.64These conflicting results could 
be due, at least in part, to the presence of microscopic 
tumour infiltration not targeted by postoperative SRS. If 
local control is important, we have to address and aim 
to obtain better brain control without neurocognitive 
deficit, as well as a better OS. This is when the combi-
nation of radiotherapy, especially SRS or HFSRT, with 
targeted drugs or immunotherapy comes in to optimise 
BM treatment.
Combination and sequencing of medical therapies with 
radiotherapy for NSCLC BMs
The irradiation anti-tumour effect is driven by direct and 
indirect effects. Irradiation can induce tumour cell death 
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SRS or HFSRT acts through the induction of apop-
tosis of endothelial cells, thus leading to tumour 
radio-sensitisation.111 More recently it has been shown 
that irradiation can induce an immune cell death 
through CD8 T-cell infiltration and by the stimulation of 
tumour antigen presentation.112 113 It has been shown 
that SRS could induce the expression of programmed 
death ligand 1 (PDL1) in tumours and that association of 
SRS and programmed cell death protein 1 (PD1) treat-
ment led to radio-sensitisation in preclinical models.114
In addition to the local effect of radiotherapy in combi-
nation with immunotherapy, radiotherapy is also able to 
induce an abscopal effect, that is, an anti-tumour effect 
outside the irradiation field. This could be of great 
interest in tumours with high metastasis potential, such 
as lung cancer.
Radiotherapy and TKIs
To optimise the effect of SRS or HFSRT in NSCLC BMs, 
the combination of targeted drugs with such irradiation 
is a promising treatment. EGFR-mutated as well as A 
LK-positive NSCLCs have a higher risk of BMs, and EGFR 
as well as ALK pathways are known to control radio resist-
ance. The association of EGFR inhibitors or ALK inhib-
itors with radiotherapy will lead to radio-sensitisation. 
Even if such inhibitors already penetrate the BBB, radi-
otherapy is known to disrupt the BBB and will help these 
inhibitors to penetrate. Several studies have shown the 
relevance of the combination of SRS or WBRT with TKIs 
with regards to intracranial progression but also, for some 
of them, in terms of OS. A pooled analysis showed that 
the combination of radiotherapy and TKIs had signifi-
cant benefits in terms of objective response rate, time to 
intra-cranial progression and OS.115 A recent retrospec-
tive study showed that WBRT and TKI treatment led to 
longer time to intracranial progression compared with 
SRS and TKI, or TKI alone.116 Another retrospective study 
showed that patients with exon 21 mutation, when treated 
with WBRT and TKI, had a significantly higher OS and 
PFS compared with those treated with TKI alone.117 No 
difference was seen for patients with exon 19 deletions. 
Also, a recent study showed that performing radiotherapy 
(SRS or WBRT) before TKI treatment significantly 
increased the median OS compared with radiotherapy 
only in the case of failure,118 suggesting that SRS before 
EGFR TKI treatment is better than TKIs alone, at least for 
patients with exon 21 mutations. However, randomised 
trials need to be performed in this area.
A few trials are currently being undertaken associating 
SRS with ALK inhibitors and these should be developed.
Radiotherapy and immunotherapy
Another possibility is the combination of immunotherapy 
and radiotherapy, particularly SRS with checkpoint inhibi-
tors. These combinations have been mostly studied in mela-
noma BMs, with SRS and ipilimumab treatment, but anti-PD1 
and SRS combinations have also been reported.119 120 Some 
studies report encouraging results even for OS, while others 
do not.121 Some recent retrospective studies have shown that 
SRS performed before and concurrently to immunotherapy 
would have better results than SRS performed after.120 122 123 
Because of the incidence of pseudo-progression with these 
combined treatments, the evaluation of their efficacy needs 
to be performed with multimodal imaging (see figure 2). 
Again, clinical trials for the evaluation of such combinations 
in NSCLC BMs in patients without mutation, but also in 
those with EGFR mutation, are needed.
neurosurgical resection of nSCLC BMs
Neurosurgical resection of BMs in patients with NSCLC 
is an indispensable treatment option in the multimodal 
management of such tumours. The subsequent initia-
tion of postoperative radiotherapy in these tumours has 
demonstrated a positive impact on OS.124 125 Further-
more, the extent of resection in NSCLC BMs is an 
important factor for patient prognosis. Thus, a complete 
‘macroscopic’ removal of surgically treated BMs results 
in a significantly better patient prognosis than an incom-
plete tumour resection.126 However, local recurrence of 
BMs after neurosurgical resection is not uncommon in 
clinical practice even after macroscopic complete resec-
tion and postoperative radiotherapy.
It was long assumed that BMs are well demarcated from 
the surrounding brain tissue. In 2013 Berghoff et al found 
in an autopsy study that only about half of the BMs show 
a well demarcated growth pattern. Tumour infiltration of 
the surrounding brain tissue of metastases was observed in 
the other half of cases. Perivascular growth into the brain 
parenchyma distant from the brain metastasis (‘vascular 
co-option’) was present in 18% of cases and diffuse infil-
tration of the surrounding brain tissue (‘diffuse infiltra-
tion’, like in a malignant glioma) was observed in 32% 
of cases.29
In a recent prospective study, Siam et al found that 
tumour infiltration of the surrounding brain tissue is a 
common finding especially in BMs from NSCLC, present 
in 75% of cases. In some of these NSCLC BMs the tumour 
infiltration was observed more than 2 mm away from the 
resection cavity.30 Thus, tumour cells might remain in 
the surrounding brain tissue despite a complete ‘macro-
scopic’ resection of BMs and result in local recurrence.
To overcome this limitation, Yoo et al proposed a ‘micro-
scopic total resection’ of single BMs in non-eloquent areas 
with additional removal of at least 5 mm of surrounding 
brain tissue. Such a microscopic total resection resulted 
in a significantly better local tumour control rate in BMs 
than conventional complete resections. However, this 
5 mm safety margin in microscopic total resections was 
arbitrarily selected126 and thus a more selective tool to 
visualise tumour infiltration of the surrounding brain 
tissue of BMs would be of interest.
5-Aminolevulinic acid
One innovative approach might be the selective visual-
isation of brain metastasis tissue with the intraoperative 
fluorescence marker 5-aminolevulinic acid (5-ALA). In a 
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recent study, Kamp et al found that BMs can be visualised 
during surgery with the assistance of 5-ALA in about two 
thirds of cases127 (see figure 3). It is not clear so far if 
the 5-ALA fluorescence technique is also able to visualise 
tumour infiltration of the surrounding tissue of BMs. This 
should be investigated in multi-centre studies.
neurosurgical interventions for the analysis of drug 
concentrations and biomarkers
Concept of ‘window of opportunity’ studies: measurement of tissue 
concentrations of antineoplastic agents in BMs
BMs have been widely considered ‘extra-axial’ lesions, 
thus not being restricted by the BBB. In contrast to 
gliomas, penetration of antineoplastic drugs from the 
intravascular space into the tumour tissue of BMs is less a 
matter of debate.62 However, solid data are scarce. Mostly, 
there has been indirect evidence for drug tissue penetra-
tion into BMs due to observation of any response in MRI 
scans after systemic chemotherapy.58 128 Recently, scores 
derived from blood values have been described to esti-
mate survival of patients with BMs.129 Only a few studies 
are available dealing with the measurement of tissue 
concentrations of antineoplastic agents in BMs. In a m 
eta-analysis of 1441 potentially relevant publications, only 
12 turned out to provide solid data on tissue concentra-
tions of chemotherapeutic drugs in BMs.54 The tissue-
to-blood ratio showed huge variations between different 
drugs which had also been used for solid tumours with 
subsequent BMs. As microsurgical resection offers 
direct access to the tissue, exposure of the patient to 
systemic therapy prior to surgery would allow the tissue 
Figure 2 Pseudo-progression after sterotactic radiosurgery (SRS) and anti-programmed cell death protein 1 (PD1) treatment 
for a lung brain metastasis. Before SRS treatment (A) and 6 months after SRS and anti-PD1 treatment (B); increase in the 
irradiated brain metastasis on T1 gadolinium MRI, without vascularisation on perfusion.
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concentration within the specimen to be quantified. Since 
the intravascular space contributes hereto, pharmacody-
namics and pharmacokinetics of the compound must be 
considered to correct the values measured accordingly. 
Prerequisites of such a study would be:
 ► the drug should be in use for cancer therapy,
 ► phase I studies are already completed,
 ► the toxicity is known and reasonably low,
 ► there are no side effects which could be relevant for 
surgery (significant immediate or early bone marrow 
toxicity, embolic or bleeding disorders),
 ► the serum half-life (tissue half-life) is known to find 
the most appropriate timing of drug delivery in rela-
tion to tissue sampling,
 ► there is a calculation of serum level to estimate the in-
fluence of the intravasal drug,
 ► intra-operative pharmacokinetics if applicable.
Morikawa et al conducted such a study for capecitabine 
and lapatinib in BMs of breast cancer.55 Capecitabine 
and lapatinib were shown to penetrate to a significant 
but variable degree into BMs of breast cancer. However, 
drug delivery to the BM tissue was variable and appeared 
in some cases too low to be effective. Overall, the tissue 
concentration varied considerably between the few cases 
under investigation, especially according to different 
preoperative dosages and timing of drug administration 
in relation to the surgical procedure. This highlights the 
importance of standardising such protocols to generate 
meaningful data. Thus, it could be crucial to elucidate 
mechanisms which limit drug concentration.
Such window-of-opportunity studies could be a prom-
ising tool to obtain information about inter-individual 
A B C D
Figure 3 Application of 5-aminolevulinic acid (5-ALA) induced fluorescence during resection of a brain metastasis. Parts of 
the brain metastasis specimen derived from resection (A) can be visualised by 5-ALA-induced fluorescence (B). After surgical 
resection of the brain metastasis (C), the surrounding, potentially still tumour-infiltrated, brain tissue demonstrates 5-ALA-
induced fluorescence (D).
Figure 4 Concept of a window-of-opportunity study to obtain information about inter-individual variation of drug 
concentrations and optimal drug dosage of new compounds for systemic treatment of brain metastases.
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variation of drug concentrations and optimal drug dosage 
of new compounds for systemic treatment of BMs to 
reduce the risk of using ineffective drugs (waste of oppor-
tunity) and missing effective drugs (loss of opportunity) 
for efficient and evidence-based planning of early phase 
II trials (see figure 4).
Identification of genetic/molecular signature
Several genetic signatures have been characterised in 
solid tumours, which are not only relevant prognostically 
but determine the oncological management.62 However, 
little is known about whether BMs share the signature 
of the primary tumour and whether multiple BMs are 
of clonal origin with the same molecular pattern. Espe-
cially in cases where the molecular profile determines 
the therapeutic management, it would be mandatory 
to know the profile of the BMs as well. Assuming the 
BMs and primary lesion would not necessarily match 
in terms of their molecular signature, at least a stereo-
tactic biopsy of the BMs would be necessary to tailor the 
treatment. The strive to personalise cancer treatment, 
also for BMs, might increase the demand for tissue anal-
ysis of BMs even in the case of a known primary lesion. 
Molecular analysis of CSF samples has been shown to 
be a useful tool to identify clinically relevant genomic 
alterations, including aberrations not found in primary 
Highlights and recommendations of the roundtable discussion
Biology and molecular alterations of non-small cell lung cancer (nSCLC) brain metastases
 ► Detailed studies of the biology have provided molecular mediators of critical processes in the metastatic colonisation of the brain that could offer 
novel avenues for translational efforts.
 ► The naive brain microenvironment can eliminate multiple brain metastasis (BM) cells by activating innate immunity mechanisms. However, 
successful BM cells have developed ways to avoid them and progress in the metastatic cascade by colonising the crucial perivascular niche in the 
brain.
 ► A critical process to initiate BMs involves the ability to co-opt pre-existing blood vessels, or grow by angiogenesis. Both mechanisms imply 
opportunities to target the growth of non-clinically detectable BMs in a preventive scenario.
 ► Exploiting the functional contribution of genomic alterations identified in human next-generation studies on BMs will be critical to evaluate the 
potential of targeting actionable mutations. In addition, these alterations could be used to track BMs using liquid biopsies.
 ► Given the specificity of the biology of BMs, the importance of the microenvironment in the progression of the disease and its potential to become a 
novel therapeutic target has started to be evaluated and pioneering clinical trials are ongoing.
 ► Improvement of experimental models that include clinically relevant situations (ie, radiation, neurosurgery, targeted therapies, specific molecular 
alterations, spontaneous models of metastases, studies in animals with intact immune system) is critical to learn more about the biology of BMs, 
and to provide a foundation for successful translation into clinical practice.
the relevance of the blood–brain barrier (BBB) for medical treatment of nSCLC BMs
 ► Many open questions about the BBB and BMs remain, but it is not justified always to expect a limited BBB penetration and a lack of meaningful 
central nervous system (CNS) activity for any given drug without testing it. Recent data suggest that even large molecules like therapeutic 
antibodies are able to penetrate the BBB in patients with BMs, at least to some extent.
treatment of nSCLC BMs
 ► CNS metastases constitute a major problem in NSCLC, particularly in patients with ALK rearrangements and even more so in those with 
ALK rearrangements pretreated with crizotinib. The CNS seems to act as a sanctuary for the emergence of metastases. In such situations, 
treatments with ALK-rearrangement-directed tyrosine kinase inhibitors (TKIs) like ceritinib, alectinib or brigatinib (although each with different 
toxicity profiles) represent a viable and effective treatment option. However, the question of an appropriate treatment sequence emerges and this 
will have to be the topic of future clinical investigations.
 ► The development of epidermal growth factor receptor (EGFR) TKIs has now reached third-generation agents with promising early results. Preclinical 
and clinical evidence shows them to be more effective, having a better blood brain penetration and the potential to overcome EGFR TKI resistance. 
Clinically, osimertinib has greater efficacy than platinum/pemetrexed in patients with T790M-positive NSCLC, including those with CNS metastases 
in a second-line setting. AZD 3759 has primarily been designed for crossing the BBB.
 ► The combination of radiotherapy and TKIs or immunotherapy is a promising treatment for NSCLC BMs but needs to be developed and validated 
in biologically driven clinical trials in terms of dose and timing. The trials should be associated with neurocognitive studies as well as metabolic 
imaging to distinguish progression from pseudo-progression.
 ► The surrounding tissue of NSCLC BMs represents an important target in the resection as well as in the medical treatment and radiosurgery/
radiotherapy of such tumours. In surgery, a ‘microscopic total resection’ with additional safe removal of the surrounding brain tissue of about 5 mm 
in non-eloquent BMs showed improvement of the local control rate. Intraoperative markers for selective visualisation of tumour infiltration into the 
surrounding brain tissue have to be further investigated.
neurosurgical interventions for the analysis of drug concentrations and biomarkers
 ► Window-of-opportunity studies could be a promising tool to obtain information about inter-individual variation of drug concentrations and optimal 
drug dosage of new compounds for systemic treatment of BMs. They could reduce the risk of using ineffective drugs (waste of opportunity) and 
missing effective drugs (loss of opportunity) for an efficient and evidence-based planning of early phase II trials.
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tumours in patients with BMs.130 Thus, liquid biopsies 
from CSF may improve personalised therapy of patients 
with BMs.
ConCLuSIon
The roundtable discussion highlighted the urgent need 
to define better treatments for prophylaxis and treatment 
of BMs in patients with NSCLC. The growing insights into 
the pathobiology of BMs and molecular treatment targets 
lead to novel therapy approaches that need to be tested in 
clinical trials enrolling patients with BMs.
author affiliations
1Clinical Division of Oncology, Department of Medicine I, Comprehensive Cancer 
Centre, Medical University Vienna – General Hospital, Vienna, Austria
2Neurology Clinic and National Center for Tumor Diseases, University Hospital 
Heidelberg, Heidelberg, Germany
3Clinical Cooperation Unit Neuro-oncology, German Cancer Consortium (DKTK), 
German Cancer Research Center (DKFZ), Heidelberg, Germany
4Brain Metastasis Group, Spanish National Cancer Research Centre (CNIO), Madrid, 
Spain
5Medical Faculty Mannheim, University of Heidelberg, Mannheim, Baden-
Württemberg, Germany
6Radiation Oncology Department, Radiobiology team 11, UMR1037 INSERM, Institut 
Universitaire du Cancer de Toulouse Oncopole, Centre de Recherche contre le 
Cancer, Toulouse, France
7Department of Neurosurgery, Medical University of Vienna (MUV), Vienna, Austria
8Department of Neurosurgery, University of California San Francisco (UCSF), San 
Francisco, USA
9Comprehensive Cancer Center–Central Nervous System Tumours Unit (CCC-CNS), 
Medical University Vienna (MUV), Vienna, Austria
10Department of Neurosurgery, Ludwig-Maximilians University, Munich-
Grosshadern, Germany and German Cancer Consortium (DKTK) at the German 
Cancer Research Centre (DKFZ), Heidelberg, Germany
funding This initiative is sponsored by AstraZeneca through the provision of an 
unrestricted educational grant. AstraZeneca has had no influence over the content 
other than a review of the paper for medical accuracy. The participants/authors 
received an honorarium for their participation from BMJ. 
Competing interests MP: Research support from Boehringer-Ingelheim, 
GlaxoSmithKline, Merck Sharp and Dohme and Roche and honoraria for lectures, 
consultation or advisory board participation from Bristol-Myers Squibb, Novartis, 
Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, 
Roche, AstraZeneca and AbbVie. FW: Research support from Boehringer Ingelheim, 
Genentech and Roche. Honoraria for lectures, consultation and advisory board 
participation from UCB, Roche and Boehringer Ingelheim. CM: Honoraria from Lilly 
and Boehringer Ingelheim. EM: Research support from AstraZeneca, Merck KGaA, 
advisory board participation from Merck KGaA. CZ: Honoraria from Ariad, Novartis, 
Boehringer Ingelheim, Roche and AstraZeneca.
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© European Society for Medical Oncology (unless otherwise stated in the text of the 
article) 2018. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
RefeRences
 1. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence 
proportions of brain metastases in patients diagnosed (1973 to 
2001) in the metropolitan Detroit cancer surveillance system. J Clin 
Oncol 2004;22:2865–72.
 2. Kohler BA, Ward E, McCarthy BJ, et al. Annual report to the nation 
on the status of cancer, 1975-2007, featuring tumors of the brain 
and other nervous system. J Natl Cancer Inst 2011;103:714–36.
 3. Toyokawa G, Seto T, Takenoyama M, et al. Insights into brain 
metastasis in patients with ALK+ lung cancer: is the brain truly a 
sanctuary? Cancer Metastasis Rev 2015;34:797–805.
 4. Mamon HJ, Yeap BY, Jänne PA, et al. High risk of brain metastases 
in surgically staged IIIA non-small-cell lung cancer patients 
treated with surgery, chemotherapy, and radiation. J Clin Oncol 
2005;23:1530–7.
 5. Felip E, Orlov S, Park K, et al. ASCEND-3: A single-arm, open-label, 
multicenter phase II study of ceritinib in ALKi-naïve adult patients 
(pts) with ALK-rearranged (ALK+) non-small cell lung cancer 
(NSCLC). J Clin Oncol 2015;33.
 6. Gahr S, Stoehr R, Geissinger E, et al. EGFR mutational status in 
a large series of Caucasian European NSCLC patients: data from 
daily practice. Br J Cancer 2013;109:1821–8.
 7. Jiang T, Su C, Li X, et al. EGFR TKIs plus WBRT demonstrated 
no survival benefit other than that of TKIs alone in patients with 
NSCLC and EGFR mutation and brain metastases. J Thorac Oncol 
2016;11:1718–28.
 8. Doebele RC, Lu X, Sumey C, et al. Oncogene status predicts 
patterns of metastatic spread in treatment-naive nonsmall cell lung 
cancer. Cancer 2012;118:4502–11.
 9. Bhatt VR, Kedia S, Kessinger A, et al. Brain metastasis in patients 
with non-small-cell lung cancer and epidermal growth factor 
receptor mutations. J Clin Oncol 2013;31:3162–4.
 10. Heon S, Yeap BY, Britt GJ, et al. Development of central nervous 
system metastases in patients with advanced non-small cell lung 
cancer and somatic EGFR mutations treated with gefitinib or 
erlotinib. Clin Cancer Res 2010;16:5873–82.
 11. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis 
(RPA) of prognostic factors in three Radiation Therapy Oncology 
Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 
1997;37:745–51.
 12. Lagerwaard FJ, Levendag PC, Nowak PJ, et al. Identification of 
prognostic factors in patients with brain metastases: a review of 
1292 patients. Int J Radiat Oncol Biol Phys 1999;43:795–803.
 13. Yates JW, Chalmer B, McKegney FP. Evaluation of patients with 
advanced cancer using the Karnofsky performance status. Cancer 
1980;45:2220–4.
 14. Fife KM, Colman MH, Stevens GN, et al. Determinants of outcome 
in melanoma patients with cerebral metastases. J Clin Oncol 
2004;22:1293–300.
 15. Bos PD, Zhang XH, Nadal C, et al. Genes that mediate breast 
cancer metastasis to the brain. Nature 2009;459:1005–9.
 16. Li B, Wang C, Zhang Y, et al. Elevated PLGF contributes to small-
cell lung cancer brain metastasis. Oncogene 2013;32:2952–62.
 17. Sevenich L, Bowman RL, Mason SD, et al. Analysis of tumour- and 
stroma-supplied proteolytic networks reveals a brain-metastasis-
promoting role for cathepsin S. Nat Cell Biol 2014;16:876–88.
 18. Jilaveanu LB, Parisi F, Barr ML, et al. PLEKHA5 as a biomarker and 
potential mediator of melanoma brain metastasis. Clin Cancer Res 
2015;21:2138–47.
 19. Kienast Y, von Baumgarten L, Fuhrmann M, et al. Real-time imaging 
reveals the single steps of brain metastasis formation. Nat Med 
2010;16:116–22.
 20. Louie E, Chen XF, Coomes A, et al. Neurotrophin-3 modulates 
breast cancer cells and the microenvironment to promote 
the growth of breast cancer brain metastasis. Oncogene 
2013;32:4064–77.
 21. Valiente M, Obenauf AC, Jin X, et al. Serpins promote cancer 
cell survival and vascular co-option in brain metastasis. Cell 
2014;156:1002–16.
 22. Winkler F. Hostile takeover: how tumours hijack pre-existing 
vascular environments to thrive. J Pathol 2017;242:267–72.
 23. Carbonell WS, Ansorge O, Sibson N, et al. The vascular basement 
membrane as ‘soil’  in brain metastasis. PLoS One 2009;4:e5857.
 24. Ghajar CM, Peinado H, Mori H, et al. The perivascular niche 
regulates breast tumour dormancy. Nat Cell Biol 2013;15:807–17.
 25. Rafii S, Butler JM, Ding BS. Angiocrine functions of organ-specific 
endothelial cells. Nature 2016;529:316–25.
 26. Malladi S, Macalinao DG, Jin X, et al. Metastatic latency and 
immune evasion through autocrine inhibition of WNT. Cell 
2016;165:45–60.
 27. Gao H, Chakraborty G, Zhang Z, et al. Multi-organ site metastatic 
reactivation mediated by non-canonical discoidin domain receptor 
1 signaling. Cell 2016;166:47–62.
 o
n






pen: first published as 10.1136/esm
oopen-2017-000262 on 26 January 2018. Downloaded from
 
Open Access
11Preusser M, et al. ESMO Open 2018;3:e000262. doi:10.1136/esmoopen-2017-000262 Preusser M, et al. ESMO Open 2018;3:e000262. doi:10.1136/esmoopen-2017-000262
 28. Ilhan-Mutlu A, Osswald M, Liao Y, et al. Bevacizumab prevents 
brain metastases formation in lung adenocarcinoma. Mol Cancer 
Ther 2016;15:702–10.
 29. Berghoff AS, Rajky O, Winkler F, et al. Invasion patterns in brain 
metastases of solid cancers. Neuro Oncol 2013;15:1664–72.
 30. Siam L, Bleckmann A, Chaung HN, et al. The metastatic infiltration 
at the metastasis/brain parenchyma-interface is very heterogeneous 
and has a significant impact on survival in a prospective study. 
Oncotarget 2015;6:29254–67.
 31. Brastianos PK, Carter SL, Santagata S, et al. Genomic 
characterization of brain metastases reveals branched evolution 
and potential therapeutic targets. Cancer Discov 2015;5:1164–77.
 32. Paik PK, Shen R, Won H, et al. Next-generation sequencing of 
stage IV squamous cell lung cancers reveals an association of PI3K 
aberrations and evidence of clonal heterogeneity in patients with 
brain metastases. Cancer Discov 2015;5:610–21.
 33. Saunus JM, Quinn MC, Patch AM, et al. Integrated genomic 
and transcriptomic analysis of human brain metastases 
identifies alterations of potential clinical significance. J Pathol 
2015;237:363–78.
 34. De Mattos-Arruda L, Mayor R, Ng CK, Ck N, et al. Cerebrospinal 
fluid-derived circulating tumour DNA better represents the 
genomic alterations of brain tumours than plasma. Nat Commun 
2015;6:8839.
 35. Lee JY, Park K, Lim SH, et al. Mutational profiling of brain 
metastasis from breast cancer: matched pair analysis of targeted 
sequencing between brain metastasis and primary breast cancer. 
Oncotarget 2015;6:43731–42.
 36. Pentsova EI, Shah RH, Tang J, et al. Evaluating cancer of the 
central nervous system through next-generation sequencing of 
cerebrospinal fluid. J Clin Oncol 2016;34:2404–15.
 37. Priedigkeit N, Hartmaier RJ, Chen Y, et al. Intrinsic subtype 
switching and acquired ERBB2/HER2 amplifications and mutations 
in breast cancer brain metastases. JAMA Oncol 2017;3:666–71.
 38. Lin Q, Balasubramanian K, Fan D, et al. Reactive astrocytes protect 
melanoma cells from chemotherapy by sequestering intracellular 
calcium through gap junction communication channels. Neoplasia 
2010;12:748–54.
 39. Kim SJ, Kim JS, Park ES, et al. Astrocytes upregulate survival 
genes in tumor cells and induce protection from chemotherapy. 
Neoplasia 2011;13:286–98.
 40. Stoletov K, Strnadel J, Zardouzian E, et al. Role of connexins in 
metastatic breast cancer and melanoma brain colonization. J Cell 
Sci 2013;126:904–13.
 41. Kim SW, Choi HJ, Lee HJ, et al. Role of the endothelin axis in 
astrocyte-and endothelial cell-mediated chemoprotection of cancer 
cells. Neuro Oncol 2014;16:1585–98.
 42. Chen Q, Boire A, Jin X, et al. Carcinoma-astrocyte gap 
junctions promote brain metastasis by cGAMP transfer. Nature 
2016;533:493–8.
 43. Steeg PS, Camphausen KA, Smith QR. Brain metastases 
as preventive and therapeutic targets. Nat Rev Cancer 
2011;11:352–63.
 44. Palmieri D, Chambers AF, Felding-Habermann B, et al. The 
biology of metastasis to a sanctuary site. Clin Cancer Res 
2007;13:1656–62.
 45. Gerstner ER, Fine RL. Increased permeability of the blood-brain 
barrier to chemotherapy in metastatic brain tumors: establishing a 
treatment paradigm. J Clin Oncol 2007;25:2306–12.
 46. Fortin D. The blood-brain barrier: its influence in the treatment 
of brain tumors metastases. Curr Cancer Drug Targets 
2012;12:247–59.
 47. Yu YJ, Zhang Y, Kenrick M, et al. Boosting brain uptake of a 
therapeutic antibody by reducing its affinity for a transcytosis target. 
Sci Transl Med 2011:3:ra44.
 48. Daneman R. The blood-brain barrier in health and disease. Ann 
Neurol 2012;72:648–72.
 49. Couch JA, Yu YJ, Zhang Y, et al. Addressing safety liabilities of TfR 
bispecific antibodies that cross the blood-brain barrier. Sci Transl 
Med 2013;5:183ra57–12.
 50. Gaudino S, Di Lella GM, Russo R, et al. Magnetic resonance 
imaging of solitary brain metastases: main findings of 
nonmorphological sequences. Radiol Med 2012;117:1225–41.
 51. Fidler IJ, Yano S, Zhang RD, et al. The seed and soil hypothesis: 
vascularisation and brain metastases. Lancet Oncol 2002;3:53–7.
 52. Lockman PR, Mittapalli RK, Taskar KS, et al. Heterogeneous 
blood-tumor barrier permeability determines drug efficacy in 
experimental brain metastases of breast cancer. Clin Cancer Res 
2010;16:5664–78.
 53. Percy DB, Ribot EJ, Chen Y, et al. In vivo characterization of 
changing blood-tumor barrier permeability in a mouse model of 
breast cancer metastasis: a complementary magnetic resonance 
imaging approach. Invest Radiol 2011;46:718–25.
 54. Pitz MW, Desai A, Grossman SA, et al. Tissue concentration of 
systemically administered antineoplastic agents in human brain 
tumors. J Neurooncol 2011;104:629–38.
 55. Morikawa A, Peereboom DM, Thorsheim HR, et al. Capecitabine 
and lapatinib uptake in surgically resected brain metastases from 
metastatic breast cancer patients: a prospective study. Neuro Oncol 
2015;17:289–95.
 56. Lewis Phillips GD, Nishimura MC, Lacap JA, et al. Trastuzumab 
uptake and its relation to efficacy in an animal model of HER2-
positive breast cancer brain metastasis. Breast Cancer Res Treat 
2017;164:581–91.
 57. Osswald M, Blaes J, Liao Y, et al. Impact of blood-brain barrier 
integrity on tumor growth and therapy response in brain 
metastases. Clin Cancer Res 2016;22:6078–87.
 58. Bartsch R, Berghoff AS, Vogl U, et al. Activity of T-DM1 in Her2-
positive breast cancer brain metastases. Clin Exp Metastasis 
2015;32:729–37.
 59. Salphati L, Heffron TP, Alicke B, et al. Targeting the PI3K pathway in 
the brain-efficacy of a PI3K inhibitor optimized to cross the blood-
brain barrier. Clin Cancer Res 2012;18:6239–48.
 60. Preusser M, Capper D, Ilhan-Mutlu A, et al. Brain metastases: 
pathobiology and emerging targeted therapies. Acta Neuropathol 
2012;123:205–22.
 61. Barlesi F, Gervais R, Lena H, et al. Pemetrexed and cisplatin 
as first-line chemotherapy for advanced non-small-cell 
lung cancer (NSCLC) with asymptomatic inoperable brain 
metastases: a multicenter phase II trial (GFPC 07-01). Ann Oncol 
2011;22:2466–70.
 62. Soffietti R, Abacioglu U, Baumert B, et al. Diagnosis and treatment 
of brain metastases from solid tumors: guidelines from the 
European Association of Neuro-Oncology (EANO). Neuro Oncol 
2017;19:162–74.
 63. Mahajan A, Ahmed S, McAleer MF, et al. Post-operative stereotactic 
radiosurgery versus observation for completely resected brain 
metastases: a single-centre, randomised, controlled, phase 3 trial. 
Lancet Oncol 2017;18:1040–8.
 64. Brown PD, Ballman KV, Cerhan JH, et al. Postoperative stereotactic 
radiosurgery compared with whole brain radiotherapy for 
resected metastatic brain disease (NCCTG N107C/CEC·3): a 
multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 
2017;18:1049–60.
 65. Brown PD, Jaeckle K, Ballman KV, et al. Effect of radiosurgery alone 
vs radiosurgery with whole brain radiation therapy on cognitive 
function in patients with 1 to 3 brain metastases: a randomized 
clinical trial. JAMA 2016;316:401–9.
 66. Aoyama H, Tago M, Shirato H. Stereotactic radiosurgery with or 
without whole-brain radiotherapy for brain metastases: secondary 
analysis of the JROSG 99-1 randomized clinical trial. JAMA Oncol 
2015;1:457–64.
 67. Gondi V, Pugh SL, Tome WA, et al. Preservation of memory 
with conformal avoidance of the hippocampal neural stem-cell 
compartment during whole-brain radiotherapy for brain metastases 
(RTOG 0933): a phase II multi-institutional trial. J Clin Oncol 
2014;32:3810–6.
 68. Brown PD, Pugh S, Laack NN, et al. Memantine for the prevention 
of cognitive dysfunction in patients receiving whole-brain 
radiotherapy: a randomized, double-blind, placebo-controlled trial. 
Neuro Oncol 2013;15:1429–37.
 69. Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery 
for patients with multiple brain metastases (JLGK0901): a multi-
institutional prospective observational study. Lancet Oncol 
2014;15:387–95.
 70. Yamamoto M, Serizawa T, Higuchi Y, et al. A multi-institutional 
prospective observational study of stereotactic radiosurgery for 
patients with multiple brain metastases (jlgk0901 study update): 
Irradiation-related complications and long-term maintenance of 
mini-mental state examination scores. Int J Radiat Oncol Biol Phys 
2017;99:31–40.
 71. Mulvenna P, Nankivell M, Barton R, et al. Dexamethasone and 
supportive care with or without whole brain radiotherapy in treating 
patients with non-small cell lung cancer with brain metastases 
unsuitable for resection or stereotactic radiotherapy (QUARTZ): 
results from a phase 3, non-inferiority, randomised trial. Lancet 
2016;388:2004–14.
 72. Mehta MP, Rodrigus P, Terhaard CH, et al. Survival and neurologic 
outcomes in a randomized trial of motexafin gadolinium and 










pen: first published as 10.1136/esm
oopen-2017-000262 on 26 January 2018. Downloaded from
 
Open Access
12 Preusser M, et al. ESMO Open 2018;3:e000262. doi:10.1136/esmoopen-2017-000262
 73. DeAngelis LM, Currie VE, Kim JH, et al. The combined use 
of radiation therapy and lonidamine in the treatment of brain 
metastases. J Neurooncol 1989;7:241–7.
 74. Eyre HJ, Ohlsen JD, Frank J, et al. Randomized trial of radiotherapy 
versus radiotherapy plus metronidazole for the treatment metastatic 
cancer to brain. A southwest oncology group study. J Neurooncol 
1984;2:325–30.
 75. Komarnicky LT, Phillips TL, Martz K, et al. A randomized phase III 
protocol for the evaluation of misonidazole combined with radiation 
in the treatment of patients with brain metastases (RTOG-7916). Int 
J Radiat Oncol Biol Phys 1991;20:53–8.
 76. Phillips TL, Scott CB, Leibel SA, et al. Results of a randomized 
comparison of radiotherapy and bromodeoxyuridine with 
radiotherapy alone for brain metastases: report of RTOG trial 89-05. 
Int J Radiat Oncol Biol Phys 1995;33:339–48.
 77. Suh JH, Stea B, Nabid A, et al. Phase III study of efaproxiral as an 
adjunct to whole-brain radiation therapy for brain metastases. J Clin 
Oncol 2006;24:106–14.
 78. Mornex F, Thomas L, Mohr P, et al. A prospective randomized 
multicentre phase III trial of fotemustine plus whole brain irradiation 
versus fotemustine alone in cerebral metastases of malignant 
melanoma. Melanoma Res 2003;13:97–103.
 79. Postmus PE, Haaxma-Reiche H, Smit EF, et al. Treatment of brain 
metastases of small-cell lung cancer: comparing teniposide and 
teniposide with whole-brain radiotherapy-a phase III study of the 
European organization for the research and treatment of cancer 
lung cancer cooperative group. J Clin Oncol 2000;18:3400–8.
 80. Ushio Y, Arita N, Hayakawa T, et al. Chemotherapy of brain 
metastases from lung carcinoma: a controlled randomized study. 
Neurosurgery 1991;28:201–5.
 81. Antonadou D, Paraskevaidis M, Sarris G, et al. Phase II randomized 
trial of temozolomide and concurrent radiotherapy in patients with 
brain metastases. J Clin Oncol 2002;20:3644–50.
 82. Verger E, Gil M, Yaya R, et al. Temozolomide and concomitant 
whole brain radiotherapy in patients with brain metastases: a phase 
II randomized trial. Int J Radiat Oncol Biol Phys 2005;61:185–91.
 83. Edelman MJ, Belani CP, Socinski MA, et al. Outcomes associated 
with brain metastases in a three-arm phase III trial of gemcitabine-
containing regimens versus paclitaxel plus carboplatin 
for advanced non-small cell lung cancer. J Thorac Oncol 
2010;5:110–6.
 84. Baik CS, Chamberlain MC, Chow LQ. Targeted therapy for brain 
metastases in EGFR-mutated and ALK-rearranged non-small-cell 
lung cancer. J Thorac Oncol 2015;10:1268–78.
 85. Togashi Y, Masago K, Masuda S, et al. Cerebrospinal fluid 
concentration of gefitinib and erlotinib in patients with non-small 
cell lung cancer. Cancer Chemother Pharmacol 2012;70:399–405.
 86. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-
paclitaxel in pulmonary adenocarcinoma. N Engl J Med 
2009;361:947–57.
 87. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard 
chemotherapy as first-line treatment for European patients with 
advanced EGFR mutation-positive non-small-cell lung cancer 
(EURTAC): a multicentre, open-label, randomised phase 3 trial. 
Lancet Oncol 2012;13:239–46.
 88. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of 
afatinib or cisplatin plus pemetrexed in patients with metastatic 
lung adenocarcinoma with EGFR mutations. J Clin Oncol 
2013;31:3327–34.
 89. Iuchi T, Shingyoji M, Sakaida T, et al. Phase II trial of gefitinib 
alone without radiation therapy for Japanese patients with brain 
metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer 
2013;82:282–7.
 90. Porta R, Sánchez-Torres JM, Paz-Ares L, et al. Brain metastases 
from lung cancer responding to erlotinib: the importance of EGFR 
mutation. Eur Respir J 2011;37:624–31.
 91. Campas C, Castañer R, Bolos J. BIBW-2992. Dual EGFR/HER2 
inhibitor, oncolytic. Drugs Future 2008;33:649.
 92. Hoffknecht P, Tufman A, Wehler T, et al. Efficacy of the irreversible 
ErbB family blocker afatinib in epidermal growth factor receptor 
(EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung 
cancer patients with brain metastases or leptomeningeal disease. J 
Thorac Oncol 2015;10:156–63.
 93. Schuler M, Wu YL, Hirsh V, et al. First-line afatinib versus 
chemotherapy in patients with non-small cell lung cancer and 
common epidermal growth factor receptor gene mutations and 
brain metastases. J Thorac Oncol 2016;11:380–90.
 94. Ballard P, Yates JW, Yang Z, et al. Preclinical comparison 
of osimertinib with other egfr-tkis in egfr-mutant nsclc brain 
metastases models, and early evidence of clinical brain metastases 
activity. Clin Cancer Res 2016;22:5130–40.
 95. Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR 
inhibitor-resistant non-small-cell lung cancer. N Engl J Med 
2015;372:1689–99.
 96. Ahn MJ, Kim DW, Kim TM, et al. Phase I study of AZD3759, a CNS 
penetrable EGFR inhibitor, for the treatment of non-small-cell lung 
cancer (NSCLC) with brain metastasis (BM) and leptomeningeal 
metastasis (LM). J Clin Oncol34 2016. (suppl; abstr 9003).
 97. Kim DW, Yang JC-H, Chen K, et al. AZD3759, an EGFR inhibitor with 
blood brain barrier (BBB) penetration for the treatment of non-small cell 
lung cancer (NSCLC) with brain metastasis (BM): Preclinical evidence 
and clinical cases. J Clin Oncol33 2015. (suppl; abstr 8016).
 98. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus 
chemotherapy in ALK-positive lung cancer. N Engl J Med 
2014;371:2167–77.
 99. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of 
crizotinib in patients with ALK-positive non-small-cell lung 
cancer: updated results from a phase 1 study. Lancet Oncol 
2012;13:1011–9.
 100. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged 
non-small-cell lung cancer. N Engl J Med 2014;371:1963–71.
 101. Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy 
of oligoprogressive disease prolongs disease control by tyrosine 
kinase inhibitors in oncogene-addicted non-small-cell lung cancer. 
J Thorac Oncol 2012;7:1807–14.
 102. Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance 
to crizotinib in patients with ALK gene rearranged non-small cell 
lung cancer. Clin Cancer Res 2012;18:1472–82.
 103. Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired 
crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl 
Med 2012;4:120ra17.
 104. Ou SH, Ahn JS, De Petris L, et al. Alectinib in crizotinib-refractory 
alk-rearranged non-small-cell lung cancer: a phase ii global study. J 
Clin Oncol 2016;34:661–8.
 105. Gettinger SN, Kim D, Tiseo M, et al, 2016. Brigatinib activity in 
patients with ALK+ NSCLC and intracranial CNS metastases in 
two clinical trials. 17th World Conference on Lung Cancer. Vienna, 
Austria: International Association for the Study of Lung Cancer
 106. Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in 
untreated ALK-positive non-small-cell lung cancer. N Engl J Med 
2017;377:829–38.
 107. Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain 
radiotherapy versus observation after radiosurgery or surgical 
resection of one to three cerebral metastases: results of the EORTC 
22952-26001 study. J Clin Oncol 2011;29:134–41.
 108. Soffietti R, Kocher M, Abacioglu UM, et al. A European organisation 
for research and treatment of cancer phase III trial of adjuvant 
whole-brain radiotherapy versus observation in patients with one to 
three brain metastases from solid tumors after surgical resection or 
radiosurgery: quality-of-life results. J Clin Oncol 2013;31:65–72.
 109. Rao G, Ahmed S, Hess K, et al. 215 Postoperative stereotactic 
radiosurgery vs observation for completely resected brain 
metastases: results of a prospective randomized study. 
Neurosurgery 2016;63:184.
 110. Jonathan EC, Bernhard EJ, McKenna WG, et al. How does radiation 
kill cells? Curr Opin Chem Biol 1999;3:77–83.
 111. Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response 
to radiotherapy regulated by endothelial cell apoptosis. Science 
2003;300:1155–9.
 112. Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative 
radiation on local tumor require CD8+ T cells: changing strategies 
for cancer treatment. Blood 2009;114:589–95.
 113. D'Souza NM, Fang P, Logan J, et al. Combining radiation therapy 
with immune checkpoint blockade for central nervous system 
malignancies. Front Oncol 2016;6:212.
 114. Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 
treatment synergistically promote antitumor immunity in mice. J Clin 
Invest 2014;124:687–95.
 115. Luo S, Chen L, Chen X, et al. Evaluation on efficacy and safety of 
tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with 
brain metastases. Oncotarget 2015;6:16725–34.
 116. Doherty MK, Korpanty GJ, Tomasini P, et al. Treatment options for 
patients with brain metastases from EGFR/ALK-driven lung cancer. 
Radiother Oncol 2017;123:195–202.
 117. Zhu Q, Sun Y, Cui Y, et al. Clinical outcome of tyrosine kinase 
inhibitors alone or combined with radiotherapy for brain metastases 
from epidermal growth factor receptor (EGFR) mutant non small cell 
lung cancer (NSCLC). Oncotarget 2017;8:13304–11.
 118. Magnuson WJ, Lester-Coll NH, Wu AJ, et al. Management of brain 
metastases in tyrosine kinase inhibitor-naïve epidermal growth 
factor receptor-mutant non-small-cell lung cancer: a retrospective 
multi-institutional analysis. J Clin Oncol 2017;35:1070–7.
 o
n






pen: first published as 10.1136/esm
oopen-2017-000262 on 26 January 2018. Downloaded from
 
Open Access
13Preusser M, et al. ESMO Open 2018;3:e000262. doi:10.1136/esmoopen-2017-000262 Preusser M, et al. ESMO Open 2018;3:e000262. doi:10.1136/esmoopen-2017-000262
 119. Choong ES, Lo S, Drummond M, et al. Survival of patients with 
melanoma brain metastasis treated with stereotactic radiosurgery and 
active systemic drug therapies. Eur J Cancer 2017;75:169–78.
 120. Ahmed KA, Kim S, Arrington J, et al. Outcomes targeting the PD-1/
PD-L1 axis in conjunction with stereotactic radiation for patients 
with non-small cell lung cancer brain metastases. J Neurooncol 
2017;133:331–8.
 121. Franceschini D, Franzese C, Navarria P, et al. Radiotherapy and 
immunotherapy: Can this combination change the prognosis of 
patients with melanoma brain metastases? Cancer Treat Rev 
2016;50:1–8.
 122. Kiess AP, Wolchok JD, Barker CA, et al. Stereotactic radiosurgery 
for melanoma brain metastases in patients receiving ipilimumab: 
safety profile and efficacy of combined treatment. Int J Radiat Oncol 
Biol Phys 2015;92:368–75.
 123. Qian JM, Yu JB, Kluger HM, et al. Timing and type of immune 
checkpoint therapy affect the early radiographic response of 
melanoma brain metastases to stereotactic radiosurgery. Cancer 
2016;122:3051–8.
 124. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of 
surgery in the treatment of single metastases to the brain. N Engl J 
Med 1990;322:494–500.
 125. Enders F, Geisenberger C, Jungk C, et al. Prognostic factors 
and long-term survival in surgically treated brain metastases 
from non-small cell lung cancer. Clin Neurol Neurosurg 
2016;142:72–80.
 126. Yoo H, Kim YZ, Nam BH, et al. Reduced local recurrence of a single 
brain metastasis through microscopic total resection. J Neurosurg 
2009;110:730–6.
 127. Kamp MA, Grosser P, Felsberg J, et al. 5-aminolevulinic acid 
(5-ALA)-induced fluorescence in intracerebral metastases: a 
retrospective study. Acta Neurochir 2012;154:223–8.
 128. Torres S, Maralani P, Verma S. Activity of T-DM1 in HER-2 positive 
central nervous system breast cancer metastases. BMJ Case Rep 
2014;2014:bcr2014205680.
 129. Berghoff AS, Wolpert F, Holland-Letz T, et al. Combining standard 
clinical blood values for improving survival prediction in patients 
with newly diagnosed brain metastases-development and validation 
of the LabBM score. Neuro Oncol 2017;19: [Epub ahead of print 17 
Jan 2017].
 130. Pentsova EI, Shah RH, Tang J, et al. Evaluating cancer of the 
central nervous system through next-generation sequencing of 
Cerebrospinal Fluid. J Clin Oncol 2016;34:2404–15.
 o
n






pen: first published as 10.1136/esm
oopen-2017-000262 on 26 January 2018. Downloaded from
 
